美諾華(603538.SH):擬推不超700萬股的2021年股票期權與限制性股票激勵計劃
格隆匯11月18日丨美諾華(603538.SH)發佈2021年股票期權與限制性股票激勵計劃(草案),擬授予激勵對象的權益數量合計為不超過700萬股,約佔計劃公吿時公司股本總額的4.68%。
其中首次授予不超過560萬股(包括股票期權386.51萬份、限制性股票173.49萬股),約佔計劃公吿時公司股本總額的3.74%;預留授予不超過140萬股(包括股票期權112萬份、限制性股票28萬股),約佔計劃公吿時公司股本總額的0.94%,預留部分佔擬授予權益總額的20%。
該激勵計劃首次授予的激勵對象共計327人,包括公司(含子公司)的董事、高級管理人員、核心骨幹員工。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.